These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19221367)

  • 1. Controlling off-label medication use.
    Gillick MR
    Ann Intern Med; 2009 Mar; 150(5):344-7. PubMed ID: 19221367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating off-label uses of anticancer drugs: time for a change.
    Sox HC
    Ann Intern Med; 2009 Mar; 150(5):353-4. PubMed ID: 19221369
    [No Abstract]   [Full Text] [Related]  

  • 3. Compendia and anticancer therapy under Medicare.
    Tillman K; Burton B; Jacques LB; Phurrough SE
    Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label cancer drug compendia found outdated and incomplete.
    Mitka M
    JAMA; 2009 Apr; 301(16):1645-6. PubMed ID: 19383947
    [No Abstract]   [Full Text] [Related]  

  • 6. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage policy and use beyond the FDA-approved label.
    McGivney WT
    J Natl Compr Canc Netw; 2006 Feb; 4(2):99-101. PubMed ID: 16451768
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
    Kaa K
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimbursement for cancer treatment: coverage of off-label drug indications.
    American Society of Clinical Oncology
    J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineoplastic agents: comparing off-label uses among authoritative drug compendia.
    Thompson DF; Keefe CC
    Hosp Formul; 1993 Jul; 28(7):641-2, 647. PubMed ID: 10127046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009 Mar; 15(2):161-5. PubMed ID: 19236131
    [No Abstract]   [Full Text] [Related]  

  • 18. Transplant recipients are vulnerable to coverage denial under Medicare Part D.
    Potter LM; Maldonado AQ; Lentine KL; Schnitzler MA; Zhang Z; Hess GP; Garrity E; Kasiske BL; Axelrod DA
    Am J Transplant; 2018 Jun; 18(6):1502-1509. PubMed ID: 29446874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
    Torres A
    Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.